載入...
Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 ≥50%, but unanswered questions remain
Na minha lista:
| 發表在: | Ann Transl Med |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
AME Publishing Company
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6685853/ https://ncbi.nlm.nih.gov/pubmed/31576334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2019.05.72 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|